NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
Clinical Trials
6 trialsNCT06957431 2025-10-24
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Washington University School of Medicine
Phase 1 Recruiting
NCT07205185 2025-10-03
A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.
Fudan University
Phase 2 Not yet recruiting
NCT03899805 2025-08-28
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT03810976 2022-06-16
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Yonsei University
Phase 2 Completed